ADVANCE: Risk of Cardiovascular Disease and Diabetes in Treatment-Naive Patients Initiating Dolutegravir- or Efavirenz-Based ART

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Clinical Care Options (CCO) expert analysis of new data from IAS 2021: COVID-19 in PWH, 2DR, LA injectable ART, novel ART in development, and MDR TB

Joseph J. Eron, Jr., MD
Program Director Princy N. Kumar, MD, FIDSA, MACP
Program Director Eric S. Daar, MD Shobha Swaminathan, MD Released: October 12, 2021

COVID-19 Outcomes in PWH, TANGO, and SALSA

FLAIR

CAPELLA and CALIBRATE

Protocol 011, Protocol 016, ZeNix

Limited treatment-emergent capsid resistance occurred after 28 weeks of treatment with oral or subcutaneous lenacapavir plus FTC/TAF from ID Week 2021 reported by Clinical Care Options (CCO)

Diapositivas descargables creadas por expertos que analizan los desarrollos clínicos más importantes en el manejo del VIH desde el año pasado

Babafemi Taiwo, MBBS
Program Director Rajesh T. Gandhi, MD Daniel R. Kuritzkes, MD Darcy Wooten, MD Released: October 4, 2021